Form 4: Madrigal Pharmaceuticals Director Receives Stock Grant

Madrigal Pharmaceuticals Director James M. Daly was granted restricted stock units and stock options on June 17, 2026, as detailed in a Form 4 filing.

Summary

• James M. Daly, a Director at Madrigal Pharmaceuticals, Inc., received a grant of 454 restricted stock units (RSUs) on June 17, 2026.
• Additionally, Mr. Daly was granted a stock option to purchase 766 shares of common stock.
• The RSUs vest on the earlier of June 17, 2027, or the Issuer's 2027 annual meeting of stockholders, contingent on continued service.
• The stock option also vests 100% on the earlier of June 17, 2027, or the Issuer's 2027 annual meeting of stockholders, also contingent on continued service.
• Following these transactions, Mr. Daly beneficially owns 3,081 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents standard director compensation and does not provide new financial performance data or strategic shifts.

Positives

• Director compensation through stock grants and options indicates management's alignment with long-term company performance.
• The vesting schedule encourages continued service and commitment to the company's success.

Future Outlook

The vesting of the RSUs and stock options is tied to continued service and specific future dates, indicating a forward-looking incentive structure for the director.

Industry Context

StockSavvy.ai notes that grants of equity to directors are a common practice in the pharmaceutical industry to incentivize leadership and align their interests with shareholders, particularly during periods of development and potential commercialization.

Stakeholder Impact

• Shareholders: The grants reinforce alignment between director compensation and company performance, potentially benefiting shareholders through motivated leadership.
• Employees: Standard practice for director compensation, unlikely to have a direct impact on other employees.
• Management: Reflects standard executive and director compensation practices.

Next Steps

• Continued service by James M. Daly through the vesting dates.
• Potential vesting of restricted stock units and stock options on or before the Issuer's 2027 annual meeting of stockholders.

Key Dates

Keywords

Form 4, Madrigal Pharmaceuticals, MDGL, Director, Stock Grant, Restricted Stock Units, Stock Option, Beneficial Ownership, SEC Filing